These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31956230)

  • 21. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
    Kaku K; Isaka H; Toyoshima J; Sakatani T
    Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
    Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
    Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
    Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
    Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Cefalu WT; Leiter LA; Yoon KH; Arias P; Niskanen L; Xie J; Balis DA; Canovatchel W; Meininger G
    Lancet; 2013 Sep; 382(9896):941-50. PubMed ID: 23850055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
    J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
    Kutoh E; Murayama T; Wada A; Hirate M
    Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
    Tahara A; Kondo Y; Takasu T; Tomiyama H
    Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
    Elgebaly A; Abdelazeim N; Abdelazeim B; El Ashal G; Mattar O; Namous L; Nasreldin N
    Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):56-72. PubMed ID: 29913526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
    Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.
    Okada K; Kotani K; Ebihara K; Yamazaki H; Ishibashi S
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1004-1008. PubMed ID: 27615008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
    Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nicolle LE; Capuano G; Fung A; Usiskin K
    Postgrad Med; 2014 Jan; 126(1):7-17. PubMed ID: 24393747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
    Matthaei S
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.